Eli Lilly and Company is slated to open its new, 334,000-square-foot R&D campus in Boston's Seaport District just over a year from now, with around 700 employees working from the site.
The facility, part of a 12-story building on Necco Street, will anchor Lilly's growing portfolio of RNA medicines. The pharmaceutical giant first announced the plans last February, but Massachusetts site head Andrew Adams told the Business Journal in an interview during the BIO International Convention that the buildout would eventually involve 700 employees, nearly triple the original estimate of 250.
STAY IN THE KNOW
 |
Watch NBC10 Boston news for free, 24/7, wherever you are. |
 |
Get Boston local news, weather forecasts, lifestyle and entertainment stories to your inbox. Sign up for NBC Boston’s newsletters. |
The so-called Lilly Institute for Genetic Medicine builds on the work the company has done in RNA-based drugs for the last several years in Kendall Square, where it has a "few hundred" employees now, Adams said. Some of those will be brought over to the Seaport space, but Lilly is also in the process of hiring more people for that buildout, with recruiting slated to ramp up next summer.
More on this story from Boston Business Journal
Get top local stories in Boston delivered to you every morning. Sign up for NBC Boston's News Headlines newsletter.
